



**New York State Medicaid  
Preferred Drug Program  
2016 Therapeutic Class Review**

The New York Medicaid Drug Utilization Review (DUR) Board intends to review the following therapeutic classes in 2016 as they pertain to the fee-for-service (FFS) Preferred Drug Program (PDP). For the therapeutic classes (provided below), new relevant clinical and/or financial information since the previous review of the class is known to exist. DUR Board meeting agendas for 2016 are under development and will be posted to the Department of Health (DoH) web-site thirty days prior to the meeting date.

<b>Therapeutic Category</b>	<b>Therapeutic Class</b>	<b>Previous Review Date</b>
Analgesics	Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) – Prescription	April 22, 2015
	Opioid Antagonists	September 18, 2014
	Opioids – Long Acting	April 22, 2015
Cardiovascular	ARBs Combinations	April 15, 2011
	Pulmonary Arterial Hypertension (PAH) Agents, Oral	September 18, 2014
Anti-Infectives	Hepatitis C Agents – Direct Acting Antivirals	February 26, 2015
Central Nervous System	Antipsychotics – Second Generation	September 17, 2015
	Antipsychotics – injectable	Initial Review
	Central Nervous System (CNS) Stimulants	April 22, 2015
	Selective Serotonin Reuptake Inhibitors	April 24, 2014
Dermatological Agents	Acne Agents – Prescription, Topical	Initial Review
	Antibiotics – Topical	June 11, 2010
Endocrine and Metabolic Agents	Insulin – Long Acting	November 4, 2010
Otics	Fluoroquinolones – Otic	April 29, 2010
Respiratory	Anticholinergics – COPD Agents	April 22, 2015
	Antihistamines – Second Generation	April 24, 2014
	Beta-2 Adrenergic Agents – Inhaled Long Acting	April 22, 2015

The current preferred and non-preferred status of drugs subject to the PDP may be viewed at [https://newyork.fhsc.com/downloads/providers/NYRx\\_PDP\\_PDL.pdf](https://newyork.fhsc.com/downloads/providers/NYRx_PDP_PDL.pdf)

At this time, no relevant new clinical and/or financial information is known to exist for the remaining PDP therapeutic classes since previously reviewed and the DoH proposes no changes to the established Commissioner's final determinations. If interested parties have new relevant clinical information, please submit to the Medicaid Pharmacy Department ([dur@health.ny.gov](mailto:dur@health.ny.gov)) in a timely manner. The DoH will consider any new relevant clinical information provided when developing future DUR Board meeting agendas.

In determining new clinical information, the previous review dates for all therapeutic classes are available on previous meeting agendas which may be viewed at [http://www.health.ny.gov/health\\_care/medicaid/program](http://www.health.ny.gov/health_care/medicaid/program)

New clinical information may include a new drug or drug product information, new indications, new safety information or new published clinical trials. **Comparative evidence is preferred, or placebo controlled when no head-to-head trials are available.**

Information in abstract form alone, posters, or unpublished data are poor quality evidence for the purpose of review and submission is discouraged.

Those wishing to submit new clinical information may do so as it becomes available. New information is preferred in an electronic format and may be submitted to [dur@health.ny.gov](mailto:dur@health.ny.gov) (please reference DUR Board PDP Review).

Please continue to monitor the DoH web-site for DUR Board meeting schedules and agendas. ([http://www.health.ny.gov/health\\_care/medicaid/program/pharmacy.htm](http://www.health.ny.gov/health_care/medicaid/program/pharmacy.htm))